Publications
2025
Schramm, W., Buchmann, D., & Hille, H. (2025). Can Pandemic Preparedness Benefit from Health-Economic Modelling? The Case for Nipah Virus. Studies in health technology and informatics, 328, 570–575. https://doi.org/10.3233/SHTI250784
2024
Eble S, Altuntas M, Stecher J, Schramm W., Exploratory study of the medical care structure of the Heilbronn-Franken region using personas, in: 68th Annual Conference of the German Society for Medical Informatics, Biometry and Epidemiology (GMDS), German Medical Science, Heilbronn, 2023.
Schramm W, Hollenbenders Y, Kurscheidt M. Explorative cost-effectiveness analysis of colorectal cancer recurrence detection with next-generation sequencing liquid biopsy in Spain, France, and Germany. Ther Adv Gastroenterol. 2024 May 10;17:17562848241248246. doi: 10.1177/17562848241248246. PMID: 38737912; PMCID: PMC11088292.
2023
Eble S, Lehmann P, Altuntas M, Stecher J, Schramm W., Exploratory study of the medical care structure of the Heilbronn-Franken region using personas, in: 68th Annual Conference of the German Society for Medical Informatics, Biometry and Epidemiology (GMDS), German Medical Science, Heilbronn, 2023. DOI: 10.3205/23gmds148. Electronic Supplementary Material to the GMDS 2023 Poster "EXPLORATORY STUDY OF THE MEDICAL CARE STRUCTURE OF THE HEILBRONN-FRANKEN REGION USING PERSONAS": PersonaPosterHHN.PDF.
Diedrich L, Brinkmann M, Dreier M, Rossol S, Schramm W, Krauth C. Is there a place for sigmoidoscopy in colorectal cancer screening? A systematic review and critical appraisal of cost-effectiveness models. PLoS One. 2023 Aug 18;18(8):e0290353. doi: 10.1371/journal.pone.0290353. PMID: 37594967; PMCID: PMC10438011.
2022
Brandl LC, Liebram C, Schramm W, Pobiruchin M. A German Smartphone-Based Self-management Tool for Psoriasis: Community-Driven Development and Evaluation of Quality-of-Life Effects. JMIR Form Res. 2022 Jul 7;6(7):e32593. doi: 10.2196/32593. PMID: 35797109; PMCID: PMC9305401.
Hackenberg B, Büttner M, Schöndorf M, Strieth S, Schramm W, Matthias C, Gouveris H. Quality of Life Assessment for Tonsillar Infections and Their Treatment. Medicina (Kaunas). 2022 Apr 25;58(5):589. doi: 10.3390/medicina58050589. PMID: 35630006; PMCID: PMC9145041.
Diedrich L, Brinkmann M, Dreier M, Schramm W, Krauth C. Additional offer of sigmoidoscopy in colorectal cancer screening in Germany: rationale and protocol of the decision-analytic modelling approach in the SIGMO study. BMJ Open. 2022 Jan 6;12(1):e050698. doi: 10.1136/bmjopen-2021-050698. PMID: 34992106; PMCID: PMC8739067.
2021
Tew M, Willis M, Asseburg C, Bennett H, Brennan A, Feenstra T, Gahn J, Gray A, Heathcote L, Herman WH, Isaman D, Kuo S, Lamotte M, Leal J, McEwan P, Nilsson A, Palmer AJ, Patel R, Pollard D, Ramos M, Sailer F, Schramm W, Shao H, Shi L, Si L, Smolen HJ, Thomas C, Tran-Duy A, Yang C, Ye W, Yu X, Zhang P, Clarke P. Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. Med Decis Making. 2021 Dec 15:272989X211065479. doi: 10.1177/0272989X211065479. Epub ahead of print. PMID: 34911405.
Larribère L, Gordejeva J, Kuhnhenn L, Kurscheidt M, Pobiruchin M, Vladimirova D, Martin M, Roser M, Schramm W, Martens UM, Eigenbrod T. Assessment of SARS-CoV-2 Infection among Healthcare Workers of a German COVID-19 Treatment Center. Int J Environ Res Public Health. 2021 Jul 1;18(13):7057. doi: 10.3390/ijerph18137057. PMID: 34281000
2020
Si, L., et al. (2020). "Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge." Value Health 23(9): 1163-1170. (Schramm W), DOI: 10.1016/j.jval.2020.04.1832, PMID: 32940234
Pobiruchin M, Zowalla R, Kurscheidt M, Schramm W. PrositNG - A Machine Learning Supported Disease Model Generation Software. Stud Health Technol Inform. 2020 Jun 26;272:151-154. doi: 10.3233/SHTI200516. PMID: 32604623.
Heinemann L, Schramm W, Koenig H, Moritz A, Vesper I, Weissmann J, Kulzer B. Benefit of Digital Tools Used for Integrated Personalized Diabetes Management: Results From the PDM-ProValue Study Program. J Diabetes Sci Technol. 2020 Mar;14(2):240-249. doi: 10.1177/1932296819867686. Epub 2019 Aug 5. PMID: 31378074; PMCID: PMC7196877.
2019
Kent S, Becker F, Feenstra T, Tran-Duy A, Schlackow I, Tew M, Zhang P, Ye W, Lizheng S, Herman W, McEwan P, Schramm W, Gray A, Leal J, Lamotte M, Willis M, Palmer AJ, Clarke P. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. Pharmacoeconomics. 2019 Nov;37(11):1305-1312. doi: 10.1007/s40273-019-00825-1. PMID: 31347104; PMCID: PMC6860461.
Schramm W, Sailer F, Pobiruchin M, Müller A, Weissman J. The Cost-Effectiveness of the PDM-ProValue Diabetes Management Program in Germany. EASD 2019, 16.-20. September 2019, Barcelona. P820.
Sailer F, Pobiruchin M, Müller A, Weissmann J, Schramm W. Macrovascular Events, Quality of Life and Mortality in the PDM-ProValue Study Program – a comparative long-term simulation. Diabetologie und Stoffwechsel 2019; 14(S 01): S13. DOI: 10.1055/s-0039-1688141
2018
Schramm W. Digital Diabetes Self-Management: A Trilateral Serial. J Diabetes Sci Technol. 2018 May;12(3):709-711. doi: 10.1177/1932296818761973. Epub 2018 Mar 7. PMID: 29514509; PMCID: PMC6154233.
2017
Heinemann L, Daenschel W, Daenschel I, Messinger D, Schramm W, Vesper I, Weissmann J, Kulzer B: Integrated personalized diabetes management (iPDM) in patients with insulin-treated T2DM: results of the PDM-ProValue study program. Poster Presentation at the Congress of the International Diabetes Federation in Abu Dhabi 2017 DOI: 10.1177/1932296815617487
Sailer F, Hunter R, Schramm W (2017): Development of a chlamydia infection model for evaluating costs and outcomes of health interventions. In: GMS Medical Informatics, Biometry and Epidemiology 13 (1). DOI: 10.3205/mibe000173
Schramm W, Rickmann J, Sailer F. Healthy, Sick, Dead – An Education Blueprint to State Transition Disease Modelling. Studies in Health Technology and Informatics Health 2017, PMID: 28679929
Seitz P, Fendrich L, Hempe H, Rickmann J, Christophidis B, Lankes S, Reimchen H, Westers M, Baumann B, Laha A, Suleder J, Sailer F, Schramm W (2017): Validation of the PROSIT CHD Type 2 Diabetes Heart Attack Model. In: Diabetologie und Stoffwechsel 12 (S 01), S1-S84. DOI: 10.1055/s-0037-1601719
Scientific Publications (peer-reviewed)
Kulzer, B.; Daenschel, W.; Daenschel, I.; Siegel, E. G.; Schramm, W.; Parkin C.G.; Messinger, D.; Weissmann, J.; Djuric, Z.; Mueller, A.; Vesper, I.; Heinemann, L.: Integrated Personalized Diabetes Management (PDM): Design of the ProValue Studies: Prospective, Cluster-Randomized, Controlled, Intervention Trials for Evaluation of the Effectiveness and Benefit of PDM in Patients With Insulin-Treated Type 2 Diabetes. In: Journal of Diabetes Science and Technology (2015). DOI: 10.1177/1932296815617487
Sailer F, Pobiruchin M, Bochum S, Martens UM, Schramm W. Prediction of 5-Year Survival with Data Mining Algorithms. Studies in Health Technology and Informatics. 2015; 213:75-78. DOI: 10.3233/978-1-61499-538-8-75; PMID: 26152957
Pobiruchin M, Kieser M, Schramm W. Leveraging Markov models to compute prevalence estimates for a regional breast cancer registry. Stud Health Technol Inform. 2013;190:237-9.
Willert T, Walker J, Schramm W. [Regional analysis of drug treatment prevalence and medication of diabetes mellitus in Germany]. Dtsch Med Wochenschr. 2012 Nov;137(46):2363-8. doi: 10.1055/s-0032-1327273. Epub 2012 Nov 6. German.
Schramm W. Self-Monitoring of Blood Glucose: One Step Forward? Journal of Diabetes Science and Technology, July 2012, Volume 6, Issue 4: pages 978–982.
Schramm W, Schöll M, Hess F. Therapy of Chronic Pain in Peripheral Diabetic Neuropathy. IQWIG pilot assessment report on the relation of benefits to costs. IQWIG Institute. (1) 1-71. 23. May 2009.
Pobiruchin M, Schramm W. [Does DMP type 2 diabetes mellitus lead to better values of HbA1c and blood pressure? An analysis regarding published quality reports] MMW Fortschr Med 2008 Apr 10.:16-21.
Martin S, Schramm W, et al. Epidemiology of Complications and Total Treatment Costs from Diagnosis of Type 2 Diabetes in Germany (ROSSO 4). Experimental Endocrinology and Diabetes. 2007 Sep;115(8):495-501.
Neeser K, Szucs T, Bulliard JL, Bachmann G, Schramm W. Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors. Value Health. 2007 Jan-Feb;10(1):42-53.
Poster award of the Swiss Society for Radiology, June 2006.
Schramm W, Haake D, Brandt A. The Economic Efficiency of Tiotropium for Chronic Obstructive Pulmonary Disease. Schweizerische Rundschau für Medizin 2005-11-16;94(46): 1803 - 1810.
Schramm W, Schoffski O, Gortz A, Liebl A. [Disease modeling in diabetes mellitus] Dtsch Med Wochenschr. 2004 Oct 22;129(43):2305-10. Review. German.
K. Neeser, U. Siebert, G. Lübben, W. Schramm: Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. Pharmacoeconomics. 2004;22(5):321-41.
Schramm W et al., the WHO St. Vincent Declaration Nephropathy Working Group: when is the optimal time for first referral of diabetes patients to a nephrologist? Diabet Med. 2003 Aug;20(8):689-90.
Schramm W. Imaging and Simulation of Diseases in Mathematical Models and Economic Assessment of Medical Outcomes. In ArzneimForsch/DrugRes, 2002, 52, 4, p. 309-351.
Piehlmeier W, Renner R, Schramm W, Schneider A, Konig A, Gottsmann M, Hardenberg R, Von Hubbenet JE, Landgraf R.: PROSIT--a quality management system for diabetic patients with nephropathy in Germany. Diabetes Nutr Metab. 2001 Apr;14(2):110-4.
Piehlmeier W, Renner R, Schramm W, Kimmerling T, Garbe S, Proetzsch R, Fahn J, Piwernetz K, Landgraf R.: Screening of diabetic patients for microalbuminuria in primary care--The PROSIT-Project. Proteinuria Screening and Intervention. Exp Clin Endocrinol Diabetes. 1999;107(4):244-51.
Piehlmeier W, Renner R, Kimmerling T, Schramm W, Garbe S, Proetzsch R, Fahn J, Piwernetz K, Landgraf R.: Evaluation of the Micral-Test S, a qualitative immunologic patient self-test for microalbuminuria: the PROSIT project. Proteinuria Screening and Intervention. Diabet Med. 1998 Oct;15(10):883-5.
General Publications
W. Schramm, M. Pobiruchin. The PROSIT Disease Modeling Community Open Source Disease Models for Cost-Benefit Assessment. Horizonte (37) 2011, p. 38-40.
W. Schramm: from "educated guess" to evidence-based decision. Management & Krankenhaus. Column "Querdenker", 03/2003.
U. Schweppe, W. Schramm. Doing the Right Thing with the Right Approach - Risk Stratification as a Method of Management in Medicine. Managed Care 7 2002 p. 34-36.
Paolo Brunetti, Carlo Lucioni, Wendelin Schramm: Terapia combinata con Pioglitazone (Actos) nel diabete di tipo 2 in Italia: valutazione farmacoeconomica, Pharmacoeconomic Issues in Type II Diabetes (Italian edition), ADIS international, ISBN: 88 88371 12 5.
W. Schramm. Rechtsmedizin pur, Lehrbuch in Karteikarten für Studenten, Börm-Bruckmeier Verlag, ISBN 3-929785-02-1.
Online Care Card Diabetes (developed by IMIB) www.diabetes-online.ch. The "Online-Gesundheits-Pass Diabetes" is an online version of the "CareCard Diabetes", a common standard document for diabetes care in Switzerland
Swiss Seminar Public Health System, Edition TrendCare, Switzerland: Chapter "Key Figures of the Swiss Health Care System", ISBN : 3-9521639-0-2
Swiss Seminar Public Health System, Edition TrendCare, Switzerland: Chapter "Disease Management for Diabetes mellitus" ISBN : 3-9521639-0-2
Landgraf R, Renner R, Schramm W. Diabetic Nephropathy in Germany – the PROSIT Project. Apotheker Journal 1997;19(7):12-15.
